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803-3 The Interleukin–174G/C Polymorphism Is a Powerful 
Predictor for Restenosis After Coronary Stent 
Implantation 
Tanja Kottmann, Cornelia Piper, Martin Farr, Dieter Fassbender, Michael Schmidt, 
Christian Goetting, Dirk Welge, Knut Kleesiek, Dieter Horstkotte, Heart Center North 
Rhine-Westphalia, Bad Oeynhausen, Germany
Background: The influence of numerous polymorphisms on restenosis after coronary
stent implantation is discussed controversially. However, there are no data regarding the
impact of the interleukin-6 (IL-6) –174G/C polymorphism on restenosis.
Methods: Between 9/01 and 2/03 96 patients (85% men, mean age 64±9 years) were
enrolled prior to coronary stent implantation. The genotypes of IL-6 (–174G/C), fibrino-
gen (-455G/A, -854G/A and HaeIII), factor VII (RQ353 and –323I/D), factor XIII
(Val34Leu), PAI-1 (4G/5G) and TFPI (-399C/T) were determined. After 6 months, all
patients underwent coronary angiography to quantify restenosis.
Results: Coronary in-stent restenosis (> 50%) was angiographically documented in 31%
of all patients. In an univariate analysis, restenosis was correlated with the G allele of –
174G/C polymorphism (45% in GG vs. 30% in GC vs. 11% in CC genotype; p<0.05). No
evidence for a significant influence on restenosis was detected for any of the other poly-
morphisms analyzed.
When analyzing the different polymorphisms, age, sex, body mass index, length of
endothelial lesion, stent length, morphology of lesion, duration of dilation and maximum
balloon pressure in a multivariate analysis, the –174G/C polymorphism was the only
parameter which turned out to be a significant predictor for coronary restenosis.
Conclusions: Of various polymorphisms only the –174G/C polymorphism is an indepen-
dent predictor for restenosis after coronary stent implantation. The risk for restenosis in
homozygous carriers of the G allele is about four times higher than in patients without G
allele.
10:00 a.m.
803-4 Analysis of Anti-apoptotic Intracellular Viral Serpins as 
Anti-atherosclerotic Agents
Liyung Liu, Kasinath Viswanathan, Erbin Dai, Peter C. Turner, Jide Togonu-Bickersteth, 
Ben Pang, Yue Li, Richard W. Moyer, Grant McFadden, Alexandra Lucas, Robarts 
Research Institute, London, ON, Canada, University of Florida, Gainesville, FL
Rationale Serine proteinase inhibitors, serpins, regulate key stages in clot formation, clot
lysis and inflammation. Two intracellular viral serpins, CrmA and Serp-2, with cysteine
proteinase and granzyme B inhibitory activity have been proven to inhibit apoptosis when
expressed inside virus infected cells. We have postulated that proteins released after
virus induced cell lysis have extracellular activities. The effects of purified CrmA and
Serp-2 proteins on early arterial apoptosis and later plaque growth after angioplasty
injury in rats were assessed and the effects of Serp-2 and crmA on human monocytes
and T-lymphocytes were also assessed.
Methods Sprague dawley rats had iliofemoral angioplasty with early (0, 12 and 72 hrs)
follow up (N=155) for arterial apoptosis and late (28 days) follow up (N=108) for arterial
plaque area. Rats were given a single intravenous (3ng-3ug) bolus of Saline, Serp-2,
CrmA, or Serp-2 active site mutants, D294A and D294E (P1 in reactive center loop
altered to Alanine and Glutamic acid respectively) immediately after surgery. Apoptosis
was measured using cell death ELISA immunoassay and substrate specific tetrapeptides
for Caspase 3 and Granzyme B. Apoptosis was also induced in human atherogenic cells,
monocytes and T-lymphocytes with Camptothecin and the anti-apoptotic activity of Serp-
2 and CrmA was examined. Anti-apoptotic gene expression was evaluated using RT
PCR.
Results Serp-2 and CrmA reduced plaque area with greater efficacy for Serp-2. Active
site mutants D294A and D294E had no effect on plaque growth. Serp-2, CrmA, D294A
and D294E reduced apoptosis and Serp-2 and CrmA reduced caspase 3 and Granzyme
B significantly at 12 - 72 hrs. The active site mutant D294A reduced Granzyme B but not
Caspase 3 while D294E reduced Caspase 3 but not Granzyme B. Crm-A effectively
attenuated Caspase 3 in human monocytic THP-1 and Serp-2 in Jurkat T-lympho-
cytes.The anti-apoptotic activity of these proteins was in part by upregulation of the Bcl-2
family genes. Conclusions Intracellular viral Serpins with cysteine proteinase inhibitory
activity displayed surprising anti-atherogenic and anti-apoptotic activity when applied
extracellularly in a rat angioplasty model.
10:15 a.m.
803-5 Dendritic Cells Contribute to In-Stent Restenosis: 
Recruitment in Early Neointima Formation After Porcine 
Aortic Stent Implantation and in Human In-Stent 
Restenosis
Izabela Tuleta, Alexander Jabs, René Andrié, Dirk Skowasch, Matthias Peuster, Berndt 
Lüderitz, Gerhard Bauriedel, Heart Center University of Bonn, Bonn, Germany, Heart 
and Diabetes Center Nordrhein Westfalen, Bad Oeynhausen, Germany
Background: We recently reported presence of dendritic cells (DCs) in rat carotid neoin-
tima early post balloon angioplasty. Since DCs are a new cell type in context with neoint-
ima formation, in the current study, we sought to assess the presence of neointimal DCs
in porcine arteries following stent implantation and in human in-stent restenosis (ISR).
Methods: Normal juvenile female domestic swine underwent stent implantation to
abdominal aortic segments. Animals were sacrified at 7, 14, 30 or 90d post stenting (n=3
per time). S100 polyclonal antibodies were used to identify DCs by immunohistochemis-
try in cross sections of the injured arteries and in 10 atherectomy probes from patients
with coronary ISR (time post stenting 5±3 months). Also in the porcine model, DC-motility
associated fascin expression was analyzed. Labelling was quantified as % labelled cells
per total count/mm2.
Results: In porcine arteries, neointima at 7d consisted of 3 layers of cells, and a high
percentage of these cells expressed the DC marker S100 (13.0±2.7%). Likewise, fascin
immunoreactivity was seen in 10.5±5.3% of neointimal cells. Subsequently at 14d,
S100+ and fascin+ cells were found predominantly in neointimal cells close to the luminal
border (14.1±5.6% for S100; 11.0±3.9% for fascin). DC marker expression in neointima
further decreased at both 30d (9.0±1.7% for S100; 2.9±1.1% for fascin) and 90d
(3.1±1.2% for S100, p<0.001; 2.9±3.0% for fascin, p=0.01 vs. 7d), but consistently
revealed luminal prevalence of this cell type. Media consistently showed no immunoreac-
tivity of S100 or fascin. In human probes, frequency of DCs was high with 9.2±5.4% at
the time of clinical ISR.
Conclusions: Dendritic cells contribute to neointima formation post stenting in a porcine
coronary model, most at early time points, as well as in human clinical ISR. Given our
previous findings of S100+ DCs in rat carotid neointima post balloon angioplasty, our
present data conclusively identify DCs as novel cell type in early vascular repair post
arterial traumatization.
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808-1 Dose Threshold for Clinical Success in Coronary 
Brachytherapy: A Nested Case-Control Study
Harsimran S. Singh, Ning Yue, Kenneth B. Roberts, Ravinder Nath, Steven Pfau, Yale 
University School of Medicine, New Haven, CT
Background: Intravascular brachytherapy is the primary treatment for coronary in-stent
restenosis. We hypothesized that differences in dose delivered to target may contribute
to treatment failures. We compared dose distribution between arteries that developed
recurrent restenosis (treatment failures) and those that remained patent at nine-months
(treatment success).
Methods: A cohort of 140 patients receiving brachytherapy for coronary in-stent resteno-
sis with four radiation delivery devices was followed to identify treatment failures and suc-
cesses. A nested case-control construct was used in which treatment failures (n=14)
were compared 1:2 to treatment successes (n=28) matched by two variables: radiation
delivery system and angiographic pattern of in-stent restenosis. At baseline, the groups
had similar patient and lesion characteristics. The dose absorbed by 90% of the artery
encompassed by the external elastic membrane (D90EEM) was calculated using intra-
vascular ultrasound (IVUS) images taken at 2-mm intervals along the treated lesion.
Dose calculations were performed using dose kernel integration techniques; the dose
kernels were generated from Monte Carlo simulations.
Results: The mean D90EEM minimum dose in treatment failures was 7.46±1.98 Gy,
while for treatment success the mean D90EEM minimum dose was significantly higher:
8.87±1.13 Gy (p=0.007). Using a minimum dose threshold of 8.4 Gy, a D90EEM minimum
dose < 8.4 Gy occurred in 13 (93%) patients with treatment failure, but in only 9 (32%)
with treatment success (p<0.001). No confounding variables were found to be statistically
significant between the cases and controls.
Conclusions: Current brachytherapy dose prescriptions result in significant inter- and
intra-lesion variation in dose at the EEM. Arteries that receive < 8.4 Gy at any point along
the external elastic membrane are more likely to be treatment failures. IVUS guided
dosimetry may be critical to assure adequate dose regardless of radiation delivery sys-
tem.
11:15 a.m.
808-2 Creatine Kinase-MB Elevation After Coronary Stenting 
in Lesions With Ruptured Plaque
Kenichi Fujii, Yoshio Kobayashi, Gary S. Mintz, David Jacoboff, Hideo Takebayashi, 
Takenori Yasuda, Issam Moussa, Roxana Mehran, George Dangas, Alexandra J. Lansky, 
Edward Kreps, Michael Collins, Gregg W. Stone, Martin B. Leon, Jeffrey W. Moses, 
Cardiovascular Research Foundation, New York, NY
Background: Elevation of serum creatine kinase MB fraction (CK-MB) after perctaneous
coronary intervention is associated with early and late mortality. We undertook this study
to evaluate the relation between CK-MB elevation and coronary stenting in lesions with
ruptured plaque.
Methods: Intravascular ultrasound (IVUS) was performed in 50 lesions with ruptured
plaque that were subsequently treated by coronary stenting. Patients with acute myocar-
dial infarction and elevated baseline CK-MB were excluded. Patients were divided into 3
groups according to CK-MB elevation after stenting: 1) no elevation (n = 32), 2) 1 to 3 x
CK-MB elevation (n = 9), and 3) >3 x CK-MB elevation (n = 9). CK-MB was measured at
baseline, 6 and 24 hours after stenting. Remodeling index was calculated as lesion exter-
nal elastic membrane (EEM) divided by reference EEM.
Results: CK-MB enzyme elevation was observed in 18 patients (36%). Baseline clinical
characteristics were similar among the 3 groups. IVUS data are shown in the Table. Mul-
tivariate analysis indicated that remodeling index (p=0.04), post-stent cross sectional
